Sylentis (PharmaMar Group) at ARVO 2019 with results from two ophthalmic drugs: tivanisirán and SYL1801

Category: General news
  • The company will present results of the HELIX clinical trial with tivanisirán for the treatment of Dry Eye Syndrome, in which an improvement in central corneal damage and results in patients with Sjögren's Syndrome are demonstrated.
  • Sylentis will also present data from the development of SYL1801 for the treatment and prevention of diseases of the retina, with administration in the form of eye drops, as opposed to the ocular injection of current treatments.

 

Madrid, 25th of April 2019. Sylentis, a pharmaceutical company belonging to the PharmaMar Group (MSE:PHM), will present results of two of its ophthalmic drugs, based on RNA interference technology: tivanisirán, for dry eye disease; and SYL1801, for the prevention and treatment of retinal diseases such as macular degeneration.

The results will be presented at the Annual Congress of the Association for Research in Vision and Ophthalmology (ARVO), to be held from April 28th to May 2nd in Vancouver, Canada. During this presentation, the results of the HELIX clinical trial with tivanisirán for the treatment of Dry Eye Syndrome will be updated, demonstrating an improvement in central corneal damage and good results in patients with Sjögren's Syndrome.

The ARVO conference is a key annual gathering of 11,000 researchers and ophthalmologists from more than 75 countries to discuss the main and most innovative advances in ophthalmic research.

"ARVO has become an essential appointment for us", says Ana Isabel Jiménez, Director of R&D and COO of Sylentis; "It is an honor to have our presentation admitted to this congress, the most important in the world in ophthalmology".

Sylentis is a leading company in the research and development of drugs based on RNA interference technology (RNAi). Its activity is focused on the discovery and development of new eye drop treatments for ophthalmological diseases with a high socio-economic impact such as dry eye disease, glaucoma, retinal diseases or ocular allergies. Sylentis is a leader in the application of this technology in the field of ophthalmology.

In fact, Jiménez points out that "at Sylentis we maintain our commitment to the development of innovative drugs in the field of ophthalmology. We are confident that our technology will provide a therapeutic option that will improve the quality of life of patients affected by ocular pathologies".

The studies presented during the congress are available at: https://www.arvo.org/annual-meeting/program/online-planner/

Sylentis Presentations at ARVO 2019:

  • Clinical results of tivanisiran, a siRNA for the treatment of dry eye disease (Panel: 6738 - B0262)
    Session: 2nd of May from 10:15 AM to 12:00 PM. Lead author: Verónica Ruz et al. Regulatory Affairs Department, Sylentis, Spain.
  • Safety & effect of tivanisiran eye drops on ocular surface: corneal sensitivity, mucin production and pro-inflammatory mediator’s expression (Panel: 6746 - B0270)
    Session: 2nd of May from 10:15 AM to 12:00 PM. Lead author: Victoria González et al. Preclinical and Clinical Department, Sylentis, Spain.
  • SYL1801: Preclinical Efficacy and Safety of a siRNA-based eye drops treatment for Age Related Macular Degeneration (Panel: 5389 - B0085)
    Session: 1st of May from 3:00 PM to 4:45 PM. Lead author: Ana Isabel Jiménez et al. R&D Department, Sylentis, Spain.

 

Explanatory videos:

What is RNA interference? https://www.youtube.com/watch?v=iXvSitR5184  

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

 

About Sylentis

Sylentis is a PharmaMar Group pharmaceutical company focused on the discovery and development of innovative therapies based on gene silencing or RNAi technologies. This technology allows the targeted design of drugs whose mechanism of action focuses on the selective inhibition of the synthesis of abnormal proteins or whose overproduction is linked to the appearance of a disease.

Sylentis has a solid drug development program in the field of ophthalmology, with tivanisirán for the treatment of dry eye[i] [ii] and bamosirán for the treatment of glaucoma, the two candidates in the most advanced clinical phases. Sylentis' product portfolio also includes candidates in the non-clinical development phase for the treatment and prevention of ocular allergies and various retinal diseases. For more information visit www.sylentis.com.

 

[i] https://clinicaltrials.gov/ct2/show/NCT03108664?term=helix&rank=5 (Febrero, 2019)

[ii] Bleau, A.-M., et al., Development of tivanisiran, a topical siRNA designed to treat dry eye disease. Integrative Clinical Medicine, 2018. 2(2)